Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.
Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.
In her study, Wong found that patients with comorbidities were 40% less likely to be treated for distant recurrence, yet this disparity did not exist for local-regional disease. Wong says that this is a topic that she would like to explore further.
FDA Approves Amivantamab Plus Chemo Combo for Advanced NSCLC With EGFR Exon 20 Insertion Mutations
March 1st 2024Amivantamab was approved by the FDA as first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations or as therapy for those whose disease progressed on or after platinum-based chemotherapy.